^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GEN2
i
Other names: GEN2, Reximmune-C2, HSV- Thymidine Kinase-m2 and hGM-CSF Genes
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
GenVivo
Drug class:
Thymidine kinase stimulant
Related drugs:
11d
GVO-1102: Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=37, Active, not recruiting, GenVivo, Inc. | Recruiting --> Active, not recruiting | N=124 --> 37
Enrollment closed • Enrollment change
|
GEN2 • Valcyte (valganciclovir)
12ms
Phase 1 Study of GEN2 in Patients with Advanced Solid Tumors (clinicaltrials.gov)
P1, N=124, Recruiting, GenVivo, Inc. | N=91 --> 124
Enrollment change • Metastases
|
GEN2 • Valcyte (valganciclovir)
1year
GEN2 Directed Cancer Immunotherapy Trial (clinicaltrials.gov)
P1, N=61, Completed, GenVivo, Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Dec 2023 | Trial primary completion date: Jun 2024 --> Dec 2023
Trial completion • Trial completion date • Trial primary completion date • Metastases
|
GEN2
over1year
Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=91, Recruiting, GenVivo, Inc.
New P1 trial • Metastases
|
GEN2 • Valcyte (valganciclovir)
over1year
GEN2 Directed Cancer Immunotherapy Trial (clinicaltrials.gov)
P1, N=61, Active, not recruiting, GenVivo, Inc. | Recruiting --> Active, not recruiting | N=122 --> 61 | Trial primary completion date: Dec 2023 --> Jun 2024
Enrollment closed • Enrollment change • Trial primary completion date • Metastases
|
GEN2
over2years
GEN2 Directed Cancer Immunotherapy Trial (clinicaltrials.gov)
P1, N=122, Recruiting, GenVivo, Inc. | Trial completion date: Mar 2023 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
Trial completion date • Trial primary completion date • Metastases
|
GEN2
Share via
